A 12-month phase 3 study of pasireotide in Cushing's disease

Annamaria Colao, Stephan Petersenn, John Newell-Price, James W Findling, Feng Gu, Mario Maldonado, Ulrike Schoenherr, David Mills, Luiz Roberto Salgado, Beverly M K Biller, Pasireotide B2305 Study Group, Ulla Feldt-Rasmussen

    542 Citationer (Scopus)

    Abstract

    Cushing's disease is associated with high morbidity and mortality. Pasireotide, a potential therapy, has a unique, broad somatostatin-receptor-binding profile, with high binding affinity for somatostatin-receptor subtype 5.
    OriginalsprogEngelsk
    TidsskriftNew England Journal of Medicine
    Vol/bind366
    Udgave nummer10
    Sider (fra-til)914-24
    Antal sider11
    ISSN0028-4793
    DOI
    StatusUdgivet - 8 mar. 2012

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'A 12-month phase 3 study of pasireotide in Cushing's disease'. Sammen danner de et unikt fingeraftryk.

    Citationsformater